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Abstract: It has long been established that mitochondrial dysfunction in Alzheimer’s disease (AD) 
patients can trigger pathological changes in cell metabolism by altering metabolic enzymes such as 
the mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), also known as 
amyloid-binding alcohol dehydrogenase (ABAD). We and others have shown that frentizole and 
riluzole derivatives can inhibit 17β-HSD10 and that this inhibition is beneficial and holds 
therapeutic merit for the treatment of AD. Here we evaluate several novel series based on 
benzothiazolylurea scaffold evaluating key structural and activity relationships required for the 
inhibition of 17β-HSD10. Results show that the most promising of these compounds have markedly 
increased potency on our previously published inhibitors, with the most promising exhibiting 
advantageous features like low cytotoxicity and target engagement in living cells. 
Keywords: Alzheimer’s disease (AD), amyloid-beta peptide (Aβ), mitochondria; 17β-
hydroxysteroid dehydrogenase type 10 (17β-HSD10), amyloid binding alcohol dehydrogenase 
(ABAD), benzothiazole 
 
1. Introduction 
There is a strong, well-documented connection between Alzheimer’s disease (AD) and 
mitochondrial dysfunction [1–3]. Mitochondrial changes in AD patients are an early event, preceding 
the onset of amyloid plaque formation, and include morphology abnormalities and changes in 
metabolism stemming from alterations in the complexes of the electron transport chain, the enzymes 
in the tricarboxylic acid cycle (TCA), and changes in components of the mitochondrial membrane 
involved in import/export flux. Mitochondria are key to the production of adenosine triphosphate 
(ATP) via the metabolism of glucose and fatty acids. Mitochondrial dysfunction in AD includes 
activity changes in many enzymes involved in these processes and contributes to the reduction in 
energy metabolism in AD [4]. Mitochondrial dysfunction is also exacerbated by the presence of 
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amyloid beta peptide (Aβ) within mitochondria [5]. One mitochondrial enzyme affected in AD is 17β-
HSD10 (17β-hydroxysteroid dehydrogenase type 10, also known as amyloid-β binding alcohol 
dehydrogenase (ABAD) or 3-Hydroxyacyl-CoA dehydrogenase). 17β-HSD10’s primary role is to 
utilise several substrates to produce energy in the β-fatty acid oxidation pathway, the energy source 
when glucose levels are low, playing a prominent role in AD, where glucose metabolism is 
significantly decreased [6]. Importantly, we and others have shown that inhibition of this enzyme is 
beneficial in both in vitro and in vivo AD models in its own right and also protects against Aβ toxicity 
in both cellular and transgenic mouse models of AD [7–12]. A current working hypothesis is that by 
inhibiting the enzyme activity of 17β-HSD10 (a contributor to the β-fatty acid oxidation pathway) 
this can help re-balance alterations in glucose metabolism observed in AD (Aitken unpublished data).  
17β-HSD10 was first identified as an Aβ binding protein in 1997 [13], a finding which has 
subsequently been confirmed using a number of techniques [5,13,14]. 17β-HSD10 is known to interact 
with the two major plaque forming isoforms of Aβ, namely Aβ(1–40) and Aβ(1–42), leading to 
distortion of the enzyme structure and inhibition of its normal function as an energy provider for 
cells [15,16]. In vitro experiments have shown that the interaction between 17β-HSD10 and Aβ is 
cytotoxic and 17β-HSD10’s function is altered with a build-up of reactive oxygen species (ROS) and 
toxins leading to mitochondrial dysfunction. Using site-directed mutagenesis and surface plasmon 
resonance protein interaction assays (SPR), Lustbader et al. identified the LD loop of the 17β-HSD10 
protein as the binding site for Aβ and subsequently synthesised a 28-amino acid peptide 
encompassing this region, which was termed the 17β-HSD10 decoy peptide [5]. Using SPR assays it 
has been shown that this 17β-HSD10 decoy peptide can prevent the binding of 17β-HSD10 to Aβ(1–
40) and Aβ(1–42). Significantly, inhibition of the interaction between 17β-HSD10 and Aβ by the 17β-
HSD10-decoy peptide was shown to translate into a cytoprotective effect in cell culture experiments. 
Cortical neurons exposed to Aβ(1–42) showed a significant increase in cell death, as measured by 
cytochrome-c release, whilst those pre-incubated with the 17β-HSD10 decoy peptide did not. 
Critically, for the first time, this work demonstrated that inhibition of the 17β-HSD10-Aβ interaction 
may target potential disease- relevant mechanisms.  
Other than the disruption of the 17β-HSD10/Aβ interaction, there is a second approach which 
may hold merit in treating AD: the direct modulation of 17β-HSD10 enzyme activity. In vitro 
experiments with neuronal-like SHSY-5Y cells exposed to the 17β-HSD10 inhibitor AG18051, showed 
a reduction in mitochondrial dysfunction and oxidative stress associated with the interaction between 
17β-HSD10 and Aβ and protected the cells from Aβ-mediated cytotoxicity [7,8]. This proved that 
inhibiting 17β-HSD10 activity may also be a viable therapeutic approach for the treatment of AD.  
In our previously published work [9] we discuss the rationale behind utilising analogues of the 
FDA-approved drugs frentizole and riluzole as inhibitors of 17β-HSD10 for potential therapeutics in 
AD. Briefly, many benzothiazole analogues have been shown to possess various biological activities 
in the central nervous system, with riluzole itself highlighted as neuroprotective. Thus, we focused 
on generating potent 17β-HSD10 inhibitors based on the benzothiazole scaffold, identifying several 
potent inhibitors (Figure 1) [9]. 
 
Figure 1. Structure of previously identified benzothiazolylurea inhibitors. 
These compounds highlighted key structural features required for 17β-HSD10 inhibition with 
the 6-trifluromethoxy and 6-halogen substitution of the benzothiazole moiety and 3-chloro, 4-
hydroxy substitution of the phenyl moiety proving the most favourable, however, with limited 
solubility the compounds were not optimal for cellular evaluation. The aim of this study was not only 
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to generate benzothiazole urea scaffolds which would show improved potency, but to also generate 
compounds with improved tolerance and less cytotoxicity within our cellular assays, i.e., better 
pharmacokinetic parameters. To that end, four series of compounds have been synthesised targeting 
the key areas of benzothiazole moiety, phenyl ring and urea linker (Figure 2).  
 
Figure 2. Design of benzothiazolylurea-based 17β-HSD10 inhibitors. 
2. Results and Discussion 
2.1. Structural Design and Chemical Synthesis 
The first series of compounds is a continuation of our previously reported work [9]. While the 
benzothiazole scaffold and urea linker were kept intact, further substitution changes into the distal 
phenyl ring were introduced, mainly at position 3 (Table 1). Methoxy substitutions at position 6 of 
benzothiazole were selected and based on the comparable inhibitory activity with halogenated 
analogues and due to the availability of starting material and improved physical chemical properties. 
Table 1. First series of prepared compounds (2–11). 
 
Compound ID R1 R2 
2 Me -OH 
3 t-butyl -OH 
4 -CN -OH 
5 -Br -OH 
6 -I -OH 
7 -NH2 -OH 
8 6-hydroxypyridin-3-yl a 
9 - -NH2 
10 -Cl -NH2 
11 -Cl -CH2OH 
a Substitution pattern replacement of whole distal phenyl ring. 
Benzothiazolylureas were formed using the two-step reaction process subsequently described. 
Initially, 6-methoxybenzo[d]thiazol-2-amine was activated with 1,1'-carbonyldiimidazole (CDI; 
Scheme 1a). Subsequently, intermediate 1 was reacted with corresponding substituted aniline (resp. 
5-aminopyridin-2-ol for final product 8) to give final di-substituted ureas (2–11). To obtain 
compounds 7, 9 and 10, N-Boc protective group was cleaved under acidic conditions (Scheme 1c) as 
the final step of their synthesis. 
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Scheme 1: Synthesis of 2–11. Reagents and conditions: (a) CDI, DCM, RT; (b) aniline derivative, 
MeCN, reflux; (c) 4 M HCl, dioxane, RT (for N-Boc protected intermediates). 
Most aniline derivatives were commercially available, but in several cases the aniline 
intermediates had to be prepared as further described: 
In general, reduction of substituted nitrobenzenes into the corresponding anilines (e.g., 12) was 
achieved with palladium on activated carbon (Pd/C) catalysed hydrogenation (Scheme 2).  
 
Scheme 2: Synthesis of aniline intermediate 12. Reagents and conditions: (a) Pd/C, H2, EtOH, RT. 
2-(Tert-butyl)phenol was selected as a starting material for introduction of tert-butyl group into 
the meta position of distal phenyl ring. Firstly, nitration was achieved with nitric acid in the presence 
of acetic acid as reaction solvent (Scheme 3a) to obtain intermediate 13. Secondly, the introduced nitro 
group was reduced to 4-amino-2-(tert-butyl)phenol (14). Initially, the reduction was attempted with 
Pd/C catalysed hydrogenation (Scheme 2). However, a complex mixture of decomposed starting 
material was received. Thus, reduction was accomplished using iron powder and ammonium 
chloride (Scheme 3b) to successfully obtain intermediate 14. 
 
Scheme 3 Synthesis of intermediates 13 and 14. Reagents and conditions: (a) HNO3/CH3COOH, RT; 
(b) Fe, NH4Cl, MeOH/H2O, RT. 
5-amino-2-hydroxybenzonitrile (15) was prepared from its methoxy analogue by demethylation 
using aluminium chloride (Scheme 4). 
 
Scheme 4 Synthesis of intermediate 15. Reagents and conditions: (a) AlCl3, DCM, reflux. 
N-Boc (de)protection had to be performed in order to obtain final compounds with the free 
amine group on the distal phenyl ring. Firstly, the amine group of nitroaniline was protected with di-
tert-butyl dicarbonate (Scheme 5a) to yield intermediates 16–18. Secondly, the nitro group was 
reduced with Pd/C catalysed hydrogenation to obtain intermediates 19–21 (Scheme 5b). Final N-Boc 
acidic deprotection was performed after the urea formation step (Scheme 1).  
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Scheme 5 Synthesis of intermediates 16–21. Reagents and conditions: (a) (Boc)2O, DMAP, THF, RT; 
(b) Pd/C, H2, EtOH, RT. 
Aniline analogue with primary alcohol group in the para position (22) was generated via 
reduction of corresponding carboxylic acid with lithium aluminium hydride (Scheme 6). 
 
Scheme 6 Synthesis of intermediate 22. Reagents and conditions: (a) LiAlH4, THF, −5 °C to RT. 
The next series was focused on selected modifications in the linker region of the scaffold, while 
the original distal phenyl ring substitution (3-chlorine-4-hydroxy) was selected in combination with 
either 6-methoxy, 6-chlorine or unsubstituted benzothiazole ring (Table 2). Additionally, to 
compliment recently published work [8,17], dimethyl phosphonate analogues were prepared as 
standards (34–36) for comparison between inter-workgroup biological evaluations along with the 
most promising 3-chloro, 4-hydroxy substitution pattern. Finally, methylation of either one or both 
nitrogen atoms of the urea linker was conducted with the aim of constraining the conjugation 
between the two aromatic moieties. 
Table 2. Second series of prepared compounds (23–49). 
Compound ID 
R1 Linker R2 
23 Cl 
 
3-Cl, 4-
OH 
24 OMe 
 
3-Cl, 4-
OH 
26 OMe 
 
3-Cl, 4-
OH 
28 OMe 
 
3-Cl, 4-
OH 
29 OMe 
 
3-OH, 4-
OH 
34 OMe 
 
4-F 
35 OMe 
 
4-OH 
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36 OMe 
 
3-
COOCH3, 
4-OH 
37 OMe 
 
3-Cl, 4-
OH 
41 - 
 
3-Cl, 4-
OH 
45 - 
 
3-Cl, 4-
OH 
46 OMe 
 
3-Cl, 4-
OH 
49 - 
 
3-Cl, 4-
OH 
Compound 23 with linker consisting of a secondary amine group was prepared by means of 
simple N-alkylation, and amides 24 and 25 were prepared in a reaction of corresponding carboxylic 
acid with CDI and corresponding amine. Compound 25 was subsequently O-demethylated to give 
the final product 26 (Scheme 7). 
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Scheme 7 Synthesis of compounds 23–26. Reagents and conditions: (a) NMP, 160 °C; (b) CDI, DMF, 
RT; (c) AlCl3, DCM, reflux. 
Compounds 28 and 29 were prepared using the general procedure for urea linker synthesis in 
reaction with CDI (Scheme 8). In case of compound 28 synthesis, the corresponding benzylamine 
intermediate (27) was first prepared from its methoxy analogue by demethylation using AlCl3 
(Scheme 8). 
 
Scheme 8 Synthesis of compounds 27–29. Reagents and conditions: (a) AlCl3, DCM, reflux; (b) MeCN, 
reflux. 
While the originally used reaction conditions proved to be troublesome to produce the desired 
compounds [17], dimethyl phosphonates (34–37) were instead prepared in a two-step process. Firstly, 
6-methoxybenzo[d]thiazol-2-amine and corresponding aldehyde were coupled at reflux conditions 
to obtain imines 30–33, which were subsequently treated with dimethyl phosphite and 1,1,3,3-
tetramethylguanidine to generate the final products in satisfactory yields (Scheme 9). 
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Scheme 9 Synthesis of phosphonate derivatives. Reagents and conditions: (a) toluene, reflux; (b) 
dimethyl phosphite, 1,1,3,3-tetramethylguanidine, THF, 65 °C. 
Compound 41 was prepared in four steps (Scheme 10). The benzothiazole moiety (38) was 
prepared from 2-iodoaniline in reaction with methylisothiocynate and tetrabutylammonium bromide 
catalysed by copper (I) chloride [18]. 3-chloro-4-methoxyaniline was treated with triphosgene to give 
the isocyanate intermediate (39), which was then reacted with the benzothiazole moiety and the 
resulting methoxy derivative (40) was demethylated using AlCl3 to give compound 41. 
 
Scheme 10 Synthesis of compound 41. Reagents and conditions: (a) MeNCS, TBABr, CuCl, DMSO, 
60–80 °C; (b) triphosgene, Et3N, DCM, 0 °C–reflux; (c) THF, RT; (d) AlCl3, toluene, reflux. 
The first step in the synthesis of products 45, 46 and 49 was to prepare corresponding 
N-methylated phenyl moieties in one (N-methylation with methyl iodide) or actually two steps (O-
demethylation using AlCl3) as shown in Scheme 11. 
 
Scheme 11 Synthesis of N-methylated aniline derivatives. Reagents and conditions: (a) CH3I, NaH, 
THF, 0 °C–RT; (b) AlCl3, toluene, reflux. 
2-chloro-4-(methylamino)phenol (43) was then treated with the corresponding intermediate (44 
and 1) produced in the reaction of benzothiazole-2-amine and 6-methoxybenzothiazole-2-amine with 
CDI (Scheme 12a) to give final products 45 and 46. 
Synthesis of final product 49 started with preparation of 3-(benzo[d]thiazol-2-yl)-1-(3-chloro-4-
methoxyphenyl)-1-methylurea (47) from the two previously generated intermediates 42 and 44 
(Scheme 12). Compound 47 was then treated with methyl iodide to methylate the other nitrogen on 
the urea linker (48). Finally, O-demethylation using AlCl3 gave the desired product 49 (Scheme 12). 
Molecules 2019, 24, 2757 9 of 25 
 
Scheme 12 Synthesis of compound with methylated urea linker. Reagents and conditions: (a) CDI, 
DCM, RT. (b) amine, MeCN, reflux. (c) CH3I, NaH, DMF, 0 °C–RT; (d) AlCl3, toluene, reflux. 
The third series of compounds (Table 3) focused on evaluating substitutions within the 
benzothiazole ring, predominantly to exploit position 6, a key area highlighted previously [9]. Our 
previous findings indicated that a 6-trifluromethoxy moiety and a 6-halogen moiety, led to an 
increased inhibitory ability towards 17β-HSD10. 
Table 3. Third series of prepared compounds (61–67). 
 
Compound ID R 
61 i-propyl 
62 t-butyl 
63 -OEt 
64 -SCF3 
65 -SCN 
66 -SO2Me 
67 -SO2CF3 
If not commercially available, the 6-substituted benzothiazole-2-amines were prepared from the 
corresponding 4-substituted anilines in reaction with potassium isocyanate and bromine (50, 51) or 
potassium isocyanate and tetramethylammonium dichloroiodate (52). 6-thiocyanatobenzothiazol-2-
amine (53) was obtained as a by-product during preparation of 6-iodobenzo[d]thiazol-2-amine 
(Scheme 13). The synthesis proceeded according to the general procedure using CDI to give 
intermediates (54–60) and final products 61–67 (Scheme 13). 
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Scheme 13 Synthesis of 6-substituted benzothiazoles. Reagents and conditions: (a1) KSCN, Br2, acetic 
acid, 10 °C–RT; (a2) KSCN, tetramethylammonium dichloroiodate, DMSO/water, RT–70 °C; (b) CDI, 
DCM, RT; (c) 4-amino-2-chlorophenol, MeCN, reflux. 
In the fourth series the benzothiazole heterocycle itself became the subject of modifications (as 
indicated in Table 4). The benzene ring was replaced with a saturated cyclohexane (71), separated 
(73) or completely removed (74), and the thiazole ring was replaced with an aliphatic cyclopentane 
(72) or replaced with an ethylene bridge (75). Further, the whole benzothiazole moiety was flipped 
and attached to urea via carbon in position 6 of the heterocycle. Moreover, the symmetric derivative 
(78) was prepared to find out whether the dimerized phenyl moiety alone is sufficient for 17β-HSD10 
inhibition. 
Table 4. Fourth series of prepared compounds (71–78). 
 
Compound ID R 
71 
 
72 
 
73 
 
74 
 
75 
 
76 
 
78 
 
The general procedure for synthesis of the urea molecules described earlier in the text (Scheme 
1) was only suitable for compounds comprising the 2-aminothiazole core (imidazolecarboxamide 
intermediates 68–70 and final products 71, 73 and 74). Therefore, for compounds 72, 75 and 76, the 
synthesis procedure had to be updated due to an increase in the solubility of imidazolecarboxamide 
intermediates, which did not allow for their simple isolation by filtration in satisfactory yields. 
Consequently, after the activation of starting compound with CDI was completed, 4-amino-2-
chlorophenol was added directly to the current reaction mixture (Scheme 14). 
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R NH
NH
O
OHCl
R NH2 CDI
H2N
OHCl
+ +
DMF
40 - 70°C
 
Scheme 14 One-pot synthesis of phenylureas 72, 75 and 76. 
The symmetric 1,3-bis(3-chloro-4-hydroxyphenyl)urea (78) was prepared in two steps (Scheme 
15). First, 3-chloro-4-methoxyaniline was treated with CDI to give 1,3-bis(3-chloro-4-
methoxyphenyl)urea (77), which was then O-demethylated in reaction with AlCl3. 
NH
O
Cl
a
NH
O O
Cl
O
Cl NH NH
O OH
Cl
HO
ClH2N
b
77 78  
Scheme 15 Synthesis of symmetric urea derivative 78. Reagents and conditions: (a) CDI, DMF, 60 °C; 
(b) AlCl3, toluene, reflux. 
2.2. Biochemical and Biophysical Evaluation 
In order to reduce attrition rates and improve assay reproducibility we have developed a high 
throughput screening (HTS) pipeline (Figure 3 [19]). In brief, compounds are screened in the 
recombinant 17β-HSD10 enzyme activity assay (Table 5, Figure 4). Our best previously published 
compounds have set the threshold of 40% remaining 17β-HSD10 activity as a minimum standard [9] 
and if compounds can better this threshold, they are further screened using our orthogonal counter 
assays, dose response assays and kinetic assessment (Table 5). Finally, if passing these criteria with 
favourable characteristics, the compounds progress into cellular evaluation through cytotoxicity 
testing and measuring 17β-HSD10 activity within cells (Table 6).  
 
Figure 3. Compound screening pipeline. 
2.3. Primary Enzyme Assay Results  
Full results for the primary nicotinamide adenine dinucleotide (NADH) assay screens are shown 
in Figure 4 including our four best previously published compounds for comparison (Figure 1) [9].  
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Our first analogue series (2–11; Table 1 and Figure 4) focused on establishing how alterations to 
the 3 and 4 position on the distal (phenolic) ring affect inhibition potency. In this series, compounds 
5 and 6 showed a huge improvement in potency with remaining 17β-HSD10 activity of 13.45% and 
6.72%, respectively, at 25 μM. A significant finding from our previous work indicated that a p-
hydroxy along m-chlorine substitution pattern displayed the most pronounced inhibitory activity [9], 
and a deviation from the 3-halogen and 4-hydroxyl pattern resulted in a dramatic decrease in 17β-
HSD10 inhibition. Our findings in this series further support this, and establish that the bulkier, 3-
bromo and 3-iodo substitutions are even more favourable at this position. Replacement of the 
phenolic hydroxyl with an amine or methylhydroxy group led to loss of activity, which further 
confirms the importance of the 4-positioned phenolic hydroxyl as was previously suggested [9]. 
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Figure 4. Primary compound in vitro evaluation (relative remaining activity at 25 μM inhibitor concentration is displayed in percentage of six independent 
measurements ± SEM; detailed results in Supplementary data). 
* Authors’ previously published most potent enzymatic data from Hroch et al. 2016 (Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential 
ABAD/17β-HSD10 modulators for Alzheimer’s disease treatment)[9]. 
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The second analogue series (23–49; Table 2) focused on evaluating changes to the urea linker. 
Unfortunately, any variation from the urea linker resulted in a dramatic decrease of inhibitory 
activity (Figure 4). This was further supported by the inclusion of compounds (34–36) previously 
published by Valasani et al. with the inclusion of our novel phosphonate compound (37) determining 
that a phosphonate linker did not increase 17β-HSD10 inhibition. Indeed, all linker variations 
resulted in negligible changes to 17β-HSD10 activity with the exception of compound 24. Although 
the secondary amide substitution (with amide nitrogen attached to benzothiazole moiety) in 
compound 24 appeared slightly more favourable than most, it was still not as potent as the original 
urea moiety and just outside of the threshold for further analysis at 47.19% 17β-HSD10 activity 
remaining at 25 μM (Figure 4). Mono and dimethylation of the urea linker to enforce sp3, rather than 
sp2 character, showed a clear detrimental effect on the activity in compound 45–49. 
The third series of compounds (61–67) focused on evaluating substitutions within the 
benzothiazole ring, predominantly to exploit position 6, a key area highlighted previously (Hroch et 
al. 2016). Our previous findings indicated that a 6-trifluromethoxy moiety and a 6-halogen moiety 
led to an increased inhibitory ability towards 17β-HSD10. This series appear to be the most promising 
displaying the largest decrease in 17β-HSD10 activity (indicated in Figure 4), in particular when 
bulky substitutions at position 6 were applied. This is particularly apparent in compounds 61 and 62 
whereby, as the functional group size increases at position 6, 17β-HSD10 activity decreases with 6-t-
butyl (62) inhibiting 17β-HSD10 by 78.36% and the 6-isopropyl substitution (61) inhibiting 17β-
HSD10 by 77.37% at 25 μM. Other key structure activity relationships in this series have been 
established through 6-thiol additions (64–67). Again, bulkier substituents produce a larger inhibitory 
effect with the 6-sulfonyl (66) less effective than the 6-trifluoromethylsulfonyl (67) with 32.16% and 
16.16% 17β-HSD10 activity remaining at 25 μM. The most potent compound in this series (65) 
introduced the pseudo-halogenic 6-thiocyanate moiety, which inhibited 17β-HSD10 activity by 
85.69% at 25 μM.  
In order to validate the importance of the benzothiazol-2-yl moiety, several structural analogues 
were prepared and evaluated in the fourth series (71–78; Table 4). Indeed, any deviation from the 
benzothiazol-2-yl moiety resulted in decreased biological activity and only the symmetrical 
compound (78) showed real inhibitory activity with 17β-HSD10 activity reduced to 40.69% at 25 μM 
(Figure 4). 
Overall, after primary screening we were left with 10 compounds which would progress down 
the pipeline: compounds 5, 6, 61, 62, 63, 64, 65, 66, 67 and 78. 
2.4. Orthogonal Counter Screens 
During our enzymatic assay development, it was noted that the assay was susceptible to false 
positives through redox cycling and aggregation mechanism [19], therefore, two orthogonal counter 
screens have been implemented to validate the primary screen results. The addition of the detergent 
Triton X-100 to the assay buffer prevents the hydrophobic interactions required for aggregation, by 
which a reduction in inhibition in the presence of Triton X-100 indicates the undesirable inhibitory 
mode of action whereby, the compound could be potentially inhibiting the enzyme through the 
indirect sequestration of the protein. Results (Table 5) identify compound 63 as a potential aggregator 
as it showed a 61% increase in 17β-HSD10 activity in the presence of Triton-X100. Compounds 65 and 
67 also showed some reduction in activity but this is much less pronounced. Given that these three 
compounds were part of a small series we decided to advance them into the next step of screening. 
With the inclusion of the strong reducing agent dithiothreitol (DTT) in the assay buffer, 
compounds can appear as a false positive as DTT is capable of generating H2O2 causing indirect 
enzyme inhibition and assay interference. The fluorescence change during the reduction of resazurin 
to resorufin can be measured as an indication of any redox cycling compounds. The results indicate 
that none of the compounds appear to be acting via this undesirable mode of action (Table 5). 
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Table 5. Biophysical characterisation of compound of interest. 
Compound ID IC50 Values (μM) 
Mechanism of 
Inhibition with 
Respect to Both 
Acetoacetyl-CoA and 
NADH 
Orthogonal Counter 
Screens: Evidence of 
Aggregation or Redox 
Cycling 
5 
1.28 
(95% CI 1.12–1.46) 
Mixed None 
6 1.86 
(95% CI 1.54–2.26) 
Mixed None 
61 5.12 
(95% CI 4.61–5.69) 
Mixed None 
62 5.29 
(95% CI 4.54–6.15) 
Mixed None 
63 1.61 
(95% CI 1.41–1.83) 
Mixed 
61% increase in 17β-
HSD10 activity within 
aggregation assay 
64 
5.21 
(95% CI 4.42–6.13) 
Mixed None 
65 
2.61 
(95% CI 2.31–2.94 
Mixed 
28.5% increase in 17β-
HSD10 activity within 
aggregation assay 
66 0.93 
(95% CI 0.82–1.05) 
Mixed None 
67 2.69 
(95% CI 2.36–3.05) 
Mixed 
12.6% increase in 17β-
HSD10 activity within 
aggregation assay 
78 6.83 
(95% CI 5.34–8.75) 
Mixed None 
2.6. Dose Response and Kinetic Evaluation 
Our most promising compounds demonstrate reasonable IC50 values of around 1–2 μM (Table 5 
and graphs in Supplementary data). Significantly, these compounds all display a mixed mechanism 
of inhibition with respect to both substrate acetoacetyl-Coenzyme A and co-factor NADH whereby 
at low concentrations they appear to act in a competitive manner, but at high concentrations they are 
inhibiting in other sites (Table 5, Hanes–Woolf plots in Supplementary data). This is favourable over 
other previously published work [7,20] as the AG18051 compound irreversibly inhibits 17β-HSD10, 
forming a covalent adduct with NADH at the active site, thus introducing a potential specificity issue.  
2.7. Cellular Screening 
Compound toxicity and potency was also assessed using HEK293 mts17β-HSD10 cells; results 
are shown in Table 6. Our fluorogenic probe, (−)-CHANA, a 17β-HSD10 substrate [21] was used to 
calculate cellular IC50 values (graphs in Supplementary data) with the exception of compounds 64, 
66, 67 and 78, which were precipitating within the assay media and not able to effectively penetrate 
into cells. Compounds 61, 62 and 63 proved to be the most potent in our cellular assay with IC50 
values of 7.88, 3.77 and 2.29 μM, respectively.  
Lactate dehydrogenase (LDH) is a colorimetric assay routinely used to quantitatively measure 
LDH released into the media from damaged cells as a biomarker for cellular cytotoxicity and 
cytolysis. HEK293 mts17β-HSD10 cells were treated with compound (100 and 25 μM) for 24 h before 
measurements were taken. At 25 μM compounds showed around 10–30% cytotoxicity, however, this 
concentration is substantially higher than the measured IC50 values and as such is not a cause for 
concern. Compound 65 showed a remarkably higher IC50 value in the (−)-CHANA assay which 
suggests that the uptake of compound by cells and 17β-HSD10 target engagement is not as favourable 
as others. 
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Table 6. Cellular cytotoxicity and potency testing in HEK293 mts17β-HSD10 cells. 
Compound ID (−)-CHANA 
IC50 values (μM) 
LDH Cytotoxicity with 
100 μM Compound 
LDH Cytotoxicity 
with 25 μM 
Compound 
5 10.39 (95% CI 5.50–19.96) 20.13 ± 4.26 13.28 ± 0.55 
6 17.04 (95% CI 9.15–31.73) 23.97 ± 3.32 23.54 ± 3.02 
61 7.88 (95% CI 5.07–12.07) 55.68 ± 2.55 28.83 ± 0.67 
62 3.77 (95% CI 2.11–6.74) 64.40 ± 3.62 27.25 ± 3.35 
63 2.29 (95% CI 1.74–3.01) 18.05± 0.96 15.98 ± 1.02 
64 - 33.35 ± 2.92 22.83 ± 0.63 
65 88.95 (95% CI 28.39–278.7) 27.41 ± 2.65 11.27 ± 0.58 
66 - 17.51± 0.46 13.59 ± 0.66 
67 - 36.05 ± 1.75 22.68 ± 2.68 
78 - 12.41 ± 0.64 11.34 ± 0.41 
3. Conclusion 
In summary, four novel series of benzothiazolylureas were designed and synthesised. All 
compounds were evaluated for 17β-HSD10 inhibitory ability in vitro, where compounds 5, 6, and 63 
showed the most promising 17β-HSD10 inhibitory activity in our enzymatic assays, although the 
orthogonal screens appear to indicate that 63 could be inhibiting 17β-HSD10 in an unfavourable 
manner. Key structure–activity relationships have been established and further validated with a urea 
linker and a 4-phenolic moiety with a 3-halogen substitution confirmed to be essential for compound 
17β-HSD10 inhibitory ability. Furthermore, a bulky substitution (e.g., t-butyl) in position 6 of the 
benzothiazole moiety appears to be the most promising, potentially occupying the chemical space 
more effectively within the binding site.  
Positively the most promising compounds were also shown to have an inhibitory effect at a 
cellular level with limited cytotoxicity and all hit compounds display a more favourable kinetic 
mechanism of action (reversible mixed inhibition) to other previously published work.  
These findings provide significant structural activity insight into our 17β-HSD10 inhibitor 
compound design and are our most promising observations to date. With further hit optimisation 
and neuronal cellular evaluation to determine if these compounds are protective against Aβ-
mediated cytotoxicity, this could potentially lead to novel class of therapeutics for AD. 
4. Materials and Methods 
4.1. General Chemistry 
All reagents and solvents were purchased from commercial sources (Sigma Aldrich, Prague, 
Czech Republic; Activate Scientific, Prien, Germany; Alfa Aesar, Kandel, Germany; Merck, 
Darmstadt, Germany; Penta Chemicals, Prague, Czech Republic and VWR, Stribrna Skalice, Czech 
Republic) and they were used without any further purification. Low boiling point (≥90% 40–60 °C) 
petroleum ether (PE) was used if not stated otherwise.  
Thin-layer chromatography (TLC) for reaction monitoring was performed on Merck aluminium 
sheets, silica gel 60 F254 (Darmstadt, Germany). Visualisation was performed either via UV (254 nm) 
or appropriate stain reagent solutions (alternatively in combination of both). Preparative column 
chromatography was performed on silica gel 60 (70–230 mesh, 63–200 μm, 60 Å pore size). Melting 
points were determined on a Stuart SMP30 melting point apparatus and are uncorrected.  
Nuclear magnetic resonance (NMR) spectra were acquired at 500/126/202 MHz (1H, 13C and 31P) 
on a Varian S500 spectrometer or at 300/75 MHz (1H and 13C) on a Varian Gemini 300 spectrometer 
(both produced by Palo Alto, CA, USA). Chemical shifts δ are given in ppm and referenced to the 
signal center of solvent peaks (DMSO-d6: δ 2.50 ppm and 39.52 ppm for 1H and 13C, respectively; 
Chloroform-d: δ 7.26 ppm and 77.16 ppm for 1H and 13C, respectively), thus indirectly correlated to 
TMS standard (δ 0 ppm). Chemical shifts δ for 31P are given in ppm and referenced to the phosphoric 
acid standard (δ 0 ppm). Coupling constants are expressed in Hz. 
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High-resolution mass spectra (HRMS) were recorded by coupled LC-MS system consisting of 
Dionex UltiMate 3000 analytical LC system and Q Exactive Plus hybrid quadrupole-orbitrap 
spectrometer (both produced by ThermoFisher Scientific, Bremen, Germany). As an ion-source, 
heated electro-spray ionization (HESI) was utilised (setting: sheath gas flow rate 40, aux gas flow rate 
10, sweep gas flow rate 2, spray voltage 3.2 kV, capillary temperature 350 °C, aux gas temperature 
300 °C, S-lens RF level 50). Positive ions were monitored in the range of 100–1500 m/z with the 
resolution set to 140,000. Obtained mass spectra were processed in Xcalibur 3.0.63 software 
(ThermoFisher Scientific, Bremen, Germany). 
Further synthetic information can be found in the Supplementary material.  
4.2. Final Products Characterization: 
The purification method is specified here only when altered from the generally used method 
described in Supplementary information. 
1-(4-Hydroxy-3-methylphenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (2)  
Yield 85%; mp: 262–263 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.55 (br s, 1H), 9.09 (s, 1H), 
8.77 (s, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.50 (d, J = 2.6 Hz, 1H), 7.18 (d, J = 2.6 Hz, 1H), 7.10 (dd, J = 8.5, 2.7 
Hz, 1H), 6.97 (dd, J = 8.8, 2.6 Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 3.79 (s, 3H), 2.12 (s, 3H); 13C-NMR (126 
MHz, DMSO-d6): δ (ppm) 157.57, 155.61, 151.75, 151.47, 142.84, 132.53, 129.56, 124.11, 122.24, 120.13, 
118.18, 114.64, 114.29, 104.87, 55.60, 16.12; HRMS (ESI) calcd for C16H16N3O3S [M + H]+ 330.09069, 
found 330.09039.  
1-(3-(Tert-butyl)-4-hydroxyphenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (3)  
Yield 73%; mp: 259–260 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.47 (br s, 1H), 9.18 (br s, 
1H), 8.79 (s, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 2.6 Hz, 1H), 7.19 (d, J = 2.6 Hz, 1H), 7.17 (dd, J = 
8.4, 2.6 Hz, 1H), 6.97 (dd, J = 8.8, 2.6 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 3.79 (s, 3H), 1.35 (s, 9H); 13C-
NMR (126 MHz, DMSO-d6): δ (ppm) 157.50, 155.61, 151.91, 151.84, 142.82, 135.53, 132.60, 129.43, 
120.20, 118.58, 118.38, 116.13, 114.28, 104.90, 55.62, 34.35, 29.25; HRMS (ESI) calcd for C19H22N3O3S [M 
+ H]+ 372.13764, found 372.13730.  
1-(3-Cyano-4-hydroxyphenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (4) 
Yield 98%; mp: 277–279 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.86 (s, 1H), 9.37 (s, 1H), 
7.76 (d, J = 2.7 Hz, 1H), 7.56 – 7.52 (m, 2H), 7.51 (d, J = 2.6 Hz, 1H), 7.01 (d, J = 9.0 Hz, 1H), 6.98 (dd, J 
= 8.8, 2.6 Hz, 1H), 3.79 (s, 3H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 157.84, 156.05, 155.71, 152.44, 
141.78, 132.24, 130.54, 126.52, 122.87, 119.79, 116.80, 116.73, 114.40, 105.00, 98.49, 55.61; HRMS (ESI) 
calcd for C16H12N4O3S [M + H]+ 341.07029, found 341.07016. 
1-(3-Bromo-4-hydroxyphenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (5)  
Yield 82%; mp: 246–247 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.71 (br s, 1H), 9.99 (s, 1H), 
8.97 (s, 1H), 7.75 (s, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.50 (s, 1H), 7.22 (d, J = 8.6 Hz, 1H), 6.97 (d, J = 8.5 Hz, 
1H), 6.92 (d, J = 8.6 Hz, 1H), 3.79 (s, 3H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 157.84, 155.67, 152.21, 
149.97, 142.25, 132.33, 131.04, 123.65, 120.14, 119.87, 116.28, 114.37, 108.86, 104.95, 55.61; HRMS (ESI) 
calcd for C15H13BrN3O3S [M + H]+ 393.98555, found 393.98489.  
1-(4-Hydroxy-3-iodophenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (6)  
Yield 85%; mp: 241–242 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 10.07 (br s, 1H), 9.05 (s, 1H), 
7.90 (d, J = 2.6 Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 2.6 Hz, 1H), 7.25 (dd, J = 8.7, 2.6 Hz, 1H), 
6.97 (dd, J = 8.8, 2.6 Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 3.79 (s, 3H); 13C-NMR (75 MHz, DMSO-d6): δ 
(ppm) 157.72, 155.67, 152.67, 152.10, 142.15, 132.35, 131.29, 129.42, 120.99, 119.93, 114.75, 114.38, 104.93, 
84.10, 55.62; HRMS (ESI) calcd for C15H13IN3O3S [M + H]+ 441.97168, found 441.97049.  
1-(3-Amino-4-hydroxyphenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (7)  
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Yield 53%; mp: 180–181 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.41 (br s, 1H), 8.76 (br s, 
1H), 8.65 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 2.6 Hz, 1H), 6.96 (dd, J = 8.8, 2.6 Hz, 1H), 6.82 (d, 
J = 2.6 Hz, 1H), 6.57 (d, J = 8.3 Hz, 1H), 6.47 (dd, J = 8.3, 2.5 Hz, 1H), 4.61 (s, 2H), 3.79 (s, 3H); 13C-NMR 
(126 MHz, DMSO-d6): δ (ppm) 157.45, 155.57, 151.34, 143.00, 140.11, 136.90, 132.57, 130.42, 122.10, 
120.22, 114.24, 107.26, 106.17, 104.84, 55.58; HRMS (ESI) calcd for C15H15N4O3S [M + H]+ 331.08594, 
found 331.08527.  
1-(6-Hydroxypyridin-3-yl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (8)  
Yield 82%; mp: 272–273 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.38 (br s, 1H), 9.08 (br s, 
1H), 7.64 (s, 1H), 7.59 (d, J = 9.1 Hz, 1H), 7.53 – 7.39 (m, 2H), 6.97 (dd, J = 9.2, 2.6 Hz, 1H), 6.36 (d, J = 
10.1 Hz, 1H), 3.79 (s, 3H); 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 160.85, 158.50, 155.83, 153.21, 142.19, 
138.04, 132.42, 127.92, 120.11, 119.28, 119.17, 114.49, 105.11, 55.78; HRMS (ESI) calcd for C14H13N4O3S 
[M + H]+ 317.07029, found 317.07004.  
1-(4-Aminophenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (9)  
Yield 93%; mp: 304–306 °C (decomp); 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.46 (br s, 1H), 
8.63 (s, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.50 (d, J = 2.6 Hz, 1H), 7.15 – 7.10 (m, 2H), 6.96 (dd, J = 8.8, 2.6 Hz, 
1H), 6.57 – 6.52 (m, 2H), 4.90 (s, 2H), 3.79 (s, 3H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 157.58, 
155.56, 151.75, 144.96, 142.74, 132.56, 127.01, 121.23, 120.12, 114.23, 114.05, 104.87, 55.58; HRMS (ESI) 
calcd for C15H15N4O2S [M + H]+ 315.09102, found 315.09058.  
1-(4-Amino-3-chlorophenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (10)  
Yield 78%y mp: 310-311 °C (decomp); 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.60 (br s, 1H), 
8.82 (s, 1H), 7.54 (d, J = 8.7 Hz, 1H), 7.50 (d, J = 2.6 Hz, 1H), 7.47 (d, J = 2.4 Hz, 1H), 7.06 (dd, J = 8.6, 2.4 
Hz, 1H), 6.97 (dd, J = 8.8, 2.6 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 5.14 (s, 2H), 3.79 (s, 3H); 13C-NMR (126 
MHz, DMSO-d6): δ (ppm) 157.69, 155.61, 151.90, 140.78, 132.42, 128.05, 120.50, 120.23, 119.97, 116.77, 
115.48, 114.29, 104.91, 55.59; HRMS (ESI) calcd for C15H14ClN4O2S [M + H]+ 349.05205, found 349.05154.  
1-(3-Chloro-4-(hydroxymethyl)phenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (11)  
Yield 92%; mp: 229–230 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.84 (br s, 1H), 9.26 (s, 1H), 
7.72 (d, J = 2.2 Hz, 1H), 7.55 (d, J = 8.7 Hz, 1H), 7.51 (d, J = 2.6 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.38 (dd, 
J = 8.4 Hz, 2.1 Hz, 1H), 6.98 (dd, J = 8.8, 2.6 Hz, 1H), 5.29 (t, J = 5.6 Hz, 1H), 4.53 (d, J = 5.2 Hz, 2H), 3.80 
(s, 3H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 157.75, 155.74, 152.27, 138.45, 133.63, 132.18, 131.19, 
128.67, 127.18, 119.85, 118.56, 117.35, 114.44, 105.01, 59.99, 55.61; HRMS (ESI) calcd for C16H15ClN3O3S 
[M + H]+ 364.05172, found 364.05103. 
2-Chloro-4-((6-chlorobenzo[d]thiazol-2-yl)amino)phenol (23) 
Yield 30%; mp: 213–214.5 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.49 (br s, 1H), 9.92 (br s, 
1H), 7.94 – 7.85 (m, 2H), 7.54 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.8, 2.6 Hz, 1H), 7.31 (dd, J = 8.6, 2.2 Hz, 
1H), 6.98 (d, J = 8.8 Hz, 1H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 162.53, 150.83, 148.56, 132.94, 
131.53, 126.01, 125.88, 120.74, 119.86, 119.74, 119.43, 118.46, 116.87; HRMS (ESI) calcd for 
C13H8Cl2N2OS [M + H]+ 310.98072, found 310.98016. 
3-Chloro-4-hydroxy-N-(6-methoxybenzo[d]thiazol-2-yl)benzamide (24) 
Yield 69%; mp: 301.5–302.5 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 12.51 (br s, 1H), 11.25 (br 
s, 1H), 8.21 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.66 (d, J = 8.9 Hz, 1H), 7.59 (s, 1H), 7.17 – 6.96 (m, 2H), 3.82 
(s, 3H); 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 164.08, 157.27, 156.85, 156.21, 142.57, 132.85, 130.34, 
128.93, 123.50, 120.96, 119.89, 116.34, 115.00, 104.66, 55.64; HRMS (ESI) calcd for C15H11ClN2O3S [M + 
H]+ 335.02517, found 335.02466. 
N-(3-Chloro-4-hydroxyphenyl)-6-methoxybenzo[d]thiazole-2-carboxamide (26) 
Yield 58%; mp: 260–261.5 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.94 (br s, 1H), 10.09 (br 
s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.94 (s, 1H), 7.80 (s, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.23 (d, J = 8.1 Hz, 1H), 
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6.97 (d, J = 8.2 Hz, 1H), 3.88 (s, 3H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 161.76, 158.62, 157.88, 
149.87, 147.05, 138.22, 130.34, 124.71, 122.22, 120.81, 119.09, 117.30, 116.36, 104.79, 55.84; HRMS (ESI) 
calcd for C15H11ClN2O3S [M + H]+ 335.02517, found 335.02466. 
1-(3-Chloro-4-hydroxybenzyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (28) 
The crude product was purified using column chromatography. 
Yield 20%; mp: 249–251 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.60 (br s, 1H), 10.08 (br s, 
1H), 7.51 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 2.6 Hz, 1H), 7.29 (d, J = 2.1 Hz, 1H), 7.13 (t, J = 5.3 Hz, 1H), 7.10 
(dd, J = 8.3, 2.1 Hz, 1H), 6.98 – 6.90 (m, 2H), 4.25 (d, J = 5.9 Hz, 2H), 3.78 (s, 3H); 13C-NMR (126 MHz, 
DMSO-d6): δ (ppm) 157.80, 155.52, 153.84, 152.01, 143.16, 132.59, 131.25, 128.80, 127.18, 120.19, 119.37, 
116.54, 114.15, 104.81, 55.57, 42.01; HRMS (ESI) calcd for C16H14ClN3O3S [M + H]+ 364.05172, found 
364.05115. 
1-(3,4-Dihydroxybenzyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea (29) 
After the reaction was completed (monitored by TLC), 1M aq. HCl was poured to the reaction 
mixture and the product was extracted to DCM. The organic layer was concentrated and the crude 
product was recrystallized from MeCN. 
Yield 50%; mp: 141.5–142 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 7.51 (d, J = 8.8 Hz, 1H), 
7.48 (d, J = 2.6 Hz, 1H), 7.15 (br s, 1H), 6.95 (dd, J = 8.8, 2.6 Hz, 1H), 6.71 (d, J = 2.0 Hz, 1H), 6.68 (d, J = 
8.0 Hz, 1H), 6.56 (dd, J = 8.0, 2.0 Hz, 1H), 4.18 (d, J = 5.5 Hz, 2H), 3.78 (s, 3H); 13C-NMR (126 MHz, 
DMSO-d6): δ (ppm) 158.51, 155.74, 153.64, 145.23, 144.41, 141.36, 131.95, 129.93, 119.61, 118.26, 115.49, 
114.93, 114.45, 105.07, 55.65, 42.68; HRMS (ESI) calcd for C16H15N3O4S [M + H]+ 346.08560, found 
346.08517. 
Dimethyl ((4-fluorophenyl)((6-methoxybenzo[d]thiazol-2-yl)amino)methyl) phosphonate (34) 
(Valasani et al. 2013).  
Yield 65%; mp: 173–174 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.48 (s, 1H), 8.76 (dd, J = 9.7, 
2.9 Hz, 1H), 7.33 – 7.27 (m, 4H), 6.82 (dd, J = 8.7, 2.7 Hz, 1H), 6.75 (d, J = 8.4 Hz, 2H), 5.54 (dd, J = 20.9, 
9.7 Hz, 1H), 3.72 (s, 3H), 3.64 (d, J = 10.5 Hz, 3H), 3.50 (d, J = 10.5 Hz, 3H); 13C-NMR (126 MHz, DMSO-
d6): δ (ppm) 163.62 (d, J = 10.0 Hz), 161.69 (dd, J = 244.1, 2.9 Hz), 154.67, 145.52, 132.10 (d, J = 2.9 Hz), 
131.87, 130.02 (dd, J = 8.3, 5.5 Hz), 118.79, 115.18 (dd, J = 21.6, 1.7 Hz), 113.09, 105.58, 53.53 (d, J = 6.8 
Hz), 53.25 (d, J = 6.8 Hz), 53.12 (d, J = 154.1 Hz); 31P NMR (202 MHz, DMSO-d6): δ (ppm) 23.56 (d, J = 
4.5 Hz); HRMS (ESI) calcd for C17H19FN2O4PS [M + H]+ 397.07817, found 397.07755.  
Dimethyl ((4-hydroxyphenyl)((6-methoxybenzo[d]thiazol-2-yl)amino)methyl) phosphonate 
(35) (Valasani et al. 2013).  
Yield 76%; mp: 217–218 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.48 (s, 1H), 8.76 (dd, J = 9.7, 
2.9 Hz, 1H), 7.33 – 7.28 (m, 4H), 6.82 (dd, J = 8.7, 2.7 Hz, 1H), 6.75 (d, J = 8.4 Hz, 2H), 5.54 (dd, J = 20.9, 
9.7 Hz, 1H), 3.72 (s, 3H), 3.64 (d, J = 10.5 Hz, 3H), 3.50 (d, J = 10.5 Hz, 3H); 13C-NMR (126 MHz, DMSO-
d6): δ (ppm) 163.70 (d, J = 10.0 Hz), 157.06 (d, J = 2.4 Hz), 154.57, 145.64, 131.82, 129.31 (d, J = 5.7 Hz), 
125.77, 118.68, 115.08, 113.01, 105.57, 55.53, 53.33 (d, J = 6.9 Hz), 53.28 (d, J = 155.2 Hz), 53.14 (d, J = 6.9 
Hz); 31P NMR (202 MHz, DMSO-d6): δ (ppm) 24.25; HRMS (ESI) calcd for C17H20N2O5PS [M + H]+ 
395.08251, found 395.08215.  
Methyl 5-((dimethoxyphosphoryl)((6-methoxybenzo[d]thiazol-2-yl)amino)methyl)-2- 
hydroxybenzoate (36) (Valasani et al. 2013)  
Yield 73%; mp: 180–181 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.53 (s, 1H), 8.90 (dd, J = 
9.6, 3.5 Hz, 1H), 7.95 (t, J = 2.3 Hz, 1H), 7.65 (dt, J = 8.7, 2.1 Hz, 1H), 7.32 (d, J = 2.7 Hz, 1H), 7.30 (d, J = 
8.7 Hz, 1H), 7.01 (d, J = 8.6 Hz, 1H), 6.82 (dd, J = 8.8, 2.7 Hz, 1H), 5.63 (dd, J = 21.3, 9.4 Hz, 1H), 3.91 (s, 
3H), 3.72 (s, 3H), 3.67 (d, J = 10.6 Hz, 3H), 3.55 (d, J = 10.6 Hz, 3H); 13C-NMR (126 MHz, DMSO-d6): δ 
(ppm) 168.86, 163.61 (d, J = 10.1 Hz), 159.53 (d, J = 2.0 Hz), 154.65, 145.52, 135.35 (d, J = 5.1 Hz), 131.88, 
129.33 (d, J = 6.0 Hz), 126.83, 118.79, 117.49, 105.58, 113.07, 113.03 (d, J = 1.9 Hz), 55.53, 53.55 (d, J = 7.1 
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Hz), 53.26 (d, J = 6.8 Hz), 52.90 (d, J = 155.2 Hz), 52.53; 31P NMR (202 MHz, DMSO-d6): δ (ppm) 23.67; 
HRMS (ESI) calcd for C19H22N2O7PS [M + H]+ 453.08798, found 453.08701.  
Dimethyl ((3-chloro-4-hydroxyphenyl)((6-methoxybenzo[d]thiazol-2-yl)amino)methyl) 
phosphonate (37)  
Yield 65%; mp: 198–199 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.28 (s, 1H), 8.77 (dd, J = 
9.7, 3.1 Hz, 1H), 7.50 (t, J = 2.1 Hz, 1H), 7.32 (d, J = 2.7 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.27 (dt, J = 8.5, 
2.1 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.82 (dd, J = 8.7, 2.6 Hz, 1H), 5.57 (dd, J = 21.0, 9.6 Hz, 1H), 3.73 (s, 
3H), 3.66 (d, J = 10.6 Hz, 3H), 3.55 (d, J = 10.6 Hz, 3H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 163.76 
(d, J = 10.1 Hz), 154.82, 152.90 (d, J = 2.4 Hz), 145.72, 132.01, 129.40 (d, J = 5.4 Hz), 128.12 (d, J = 5.9 Hz), 
127.58, 119.66 (d, J = 2.2 Hz), 118.94, 116.52, 113.25, 105.76, 55.71, 53.66 (d, J = 6.8 Hz), 53.41 (d, J = 7.0 
Hz), 52.95 (d, J = 155.3 Hz); 31P NMR (202 MHz, DMSO-d6): δ (ppm) 23.71; HRMS (ESI) calcd for 
C17H19ClN2O5PS [M + H]+ 429.04353, found 429.0425.  
1-(Benzo[d]thiazol-2-yl)-3-(3-chloro-4-hydroxyphenyl)-1-methylurea (41) 
Yield 83%; mp: 171–172 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.02 (s, 1H), 9.47 (s, 1H), 
7.94 – 7.84 (m, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 2.6 Hz, 1H), 7.45 – 7.35 (m, 1H), 7.31 (dd, J = 8.8, 
2.6 Hz, 1H), 7.28 – 7.19 (m, 1H), 6.96 (d, J = 8.7 Hz, 1H), 3.75 (s, 3H); 13C-NMR (126 MHz, DMSO-d6): 
δ (ppm) 161.45, 153.45, 149.66, 148.45, 132.76, 130.50, 125.80, 123.42, 123.09, 121.95, 121.12, 120.29, 
119.01, 116.29, 34.55 (d, J = 3.0 Hz); HRMS (ESI) calcd for C15H12ClN3O2S [M + H]+ 334.04115, found 
334.04080. 
3-(Benzo[d]thiazol-2-yl)-1-(3-chloro-4-hydroxyphenyl)-1-methylurea (45) 
The crude product was dissolved in Et2O and filtered. To the filtrate was added PE and the 
solution was left to crystallize in a freezer. Filtration gave the desired pure product. 
Yield 53%; mp: 139–141 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.28 (br s, 1H), 7.81 (d, J = 
7.5 Hz, 1H), 7.45 (br s, 1H), 7.38 – 7.30 (m, 2H), 7.19 (t, J = 7.9 Hz, 1H), 7.11 (dd, J = 8.6, 2.5 Hz, 1H), 
6.99 (d, J = 8.6 Hz, 1H), 3.26 (s, 3H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 151.90, 135.11, 128.70, 
126.89, 125.94, 122.65, 121.62, 119.46, 116.66, 37.93; HRMS (ESI) calcd for C15H12ClN3O2S [M + H]+ 
334.0412, found 334.0414. 
1-(3-Chloro-4-hydroxyphenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)-1-methylurea (46) 
The crude product was purified using column chromatography. 
Yield 50%; mp: 220 °C decomp.; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.28 (br s, 1H), 7.45 (d, 
J = 2.2 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.36 (d, J = 2.5 Hz, 1H), 7.11 (dd, J = 8.6, 2.5 Hz, 1H), 6.98 (d, J 
= 8.6 Hz, 1H), 6.94 (dd, J = 8.8, 2.6 Hz, 1H), 3.77 (s, 3H), 3.25 (s, 3H); 13C-NMR (126 MHz, DMSO-d6): δ 
(ppm) 155.57, 151.97, 134.94, 131.53, 128.78, 126.95, 119.52, 118.40, 116.70, 114.18, 105.12, 55.60, 37.94; 
HRMS (ESI) calcd for C16H14ClN3O3S [M + H]+ 364.0517, found 364.0530. 
1-(Benzo[d]thiazol-2-yl)-3-(3-chloro-4-hydroxyphenyl)-1,3-dimethylurea (49) 
Yield 65%; mp: 227–228.5 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.09 (s, 1H), 7.74 (d, J = 
7.7 Hz, 1H), 7.47 – 7.37 (m, 2H), 7.36 (d, J = 2.4 Hz, 1H), 7.23 (t, J = 7.9 Hz, 1H), 7.13 (dd, J = 8.6, 2.2 Hz, 
1H), 6.95 (d, J = 8.7 Hz, 1H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 165.20, 160.92, 150.53, 137.50, 
136.58, 127.60, 126.56, 125.93, 125.38, 123.01, 122.40, 118.67, 115.86, 111.35, 37.16, 31.51; HRMS (ESI) 
calcd for C16H14ClN3O2S [M + H]+ 348.05680, found 348.05661. 
1-(3-Chloro-4-hydroxyphenyl)-3-(6-isopropylbenzo[d]thiazol-2-yl)urea (61) 
Yield 43%; mp: 246–248 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.83 (br s, 1H), 9.91 (br s, 
1H), 9.02 (s, 1H), 7.74 (s, 1H), 7.61 (d, J = 2.4 Hz, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.26 (dd, J = 8.3, 1.5 Hz, 
1H), 7.19 (dd, J = 8.7, 2.4 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 6.73 (d, J = 8.7 Hz, 1H), 2.97 (sept, J = 6.9 Hz, 
1H), 1.23 (d, J = 6.9 Hz, 6H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 159.33, 152.47, 148.89, 146.08, 
143.46, 131.02, 130.84, 124.67, 120.74, 119.41, 119.33, 118.68, 116.64, 33.41, 24.17; HRMS (ESI) calcd for 
C17H16ClN3O2S [M + H]+ 362.0725, found 362.0721. 
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1-(6-(Tert-butyl)benzo[d]thiazol-2-yl)-3-(3-chloro-4-hydroxyphenyl)urea (62) 
Yield 66%; mp: 238–240 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.75 (s, 1H), 7.90 (d, J = 1.9 
Hz, 1H), 7.60 (d, J = 2.6 Hz, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.43 (dd, J = 8.5, 2.0 Hz, 1H), 7.18 (dd, J = 8.8, 
2.6 Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H), 1.32 (s, 9H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 159.43, 
152.17, 148.89, 145.88, 145.02, 130.87, 130.77, 123.74, 120.40, 119.36, 119.08, 118.41, 117.78, 116.74, 34.62, 
31.45; HRMS (ESI) calcd for C18H18ClN3O2S [M + H]+ 376.0881, found 376.0882. 
1-(3-Chloro-4-hydroxyphenyl)-3-(6-ethoxybenzo[d]thiazol-2-yl)urea (63) 
Yield 90%; mp: 255–257 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 10.72 (br s, 1H), 9.92 (s, 1H), 
9.00 (s, 1H), 7.60 (s, 1H), 7.57–7.36 (m, 2H), 7.18 (d, J = 7.9 Hz, 1H), 7.04 – 6.84 (m, 2H), 4.04 (q, J = 6.9 
Hz, 2H), 1.33 (t, J = 7.0 Hz, 3H); 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 157.76, 154.90, 152.19, 148.90, 
141.98, 132.33, 130.82, 120.74, 119.89, 119.41, 119.34, 116.67, 114.76, 105.59, 63.59, 14.75; HRMS (ESI) 
calcd for C16H14ClN3O3S [M + H]+ 364.0517, found 364.0521. 
1-(3-Chloro-4-hydroxyphenyl)-3-(6-((trifluoromethyl)thio)benzo[d]thiazol-2-yl)urea (64) 
Yield 24%; mp: 256–258 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 11.04 (br s, 1H), 9.95 (br s, 
1H), 9.03 (s, 1H), 8.37 (d, J = 1.8 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.67 (dd, J = 8.4, 1.9 Hz, 1H), 7.59 (d, 
J = 2.6 Hz, 1H), 7.19 (dd, J = 8.8, 2.6 Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H); 13C-NMR (126 MHz, DMSO-d6): δ 
(ppm) 162.27, 152.10, 150.64, 149.08, 134.08, 132.73, 130.61, 130.28, 129.69 (q, J = 308.1 Hz), 120.65, 
120.34, 119.38, 119.33, 116.74, 115.69 (q, J = 2.1 Hz); HRMS (ESI) calcd for C15H9ClF3N3O2S2 [M + H]+ 
419.9850, found 419.9873. 
1-(3-Chloro-4-hydroxyphenyl)-3-(6-thiocyanatobenzo[d]thiazol-2-yl)urea (65) 
Yield 80%; mp: 251–253 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 11.04 (br s, 1H), 9.97 (br s, 
1H), 9.13 (br s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 8.5, 2.0 Hz, 1H), 7.60 
(d, J = 2.6 Hz, 1H), 7.19 (dd, J = 8.8, 2.6 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H); 13C-NMR (126 MHz, DMSO-
d6): δ (ppm) 161.91, 152.15, 149.47, 149.14, 133.11, 130.46, 129.54, 125.55, 121.00, 120.73, 119.66, 119.35, 
116.75, 116.66, 112.20; HRMS (ESI) calcd for C15H9ClN4O2S2 [M + H]+ 376.9928, found 376.9939. 
1-(3-Chloro-4-hydroxyphenyl)-3-(6-(methylsulfonyl)benzo[d]thiazol-2-yl)urea (66) 
Yield 78%; mp: 293–295 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 11.16 (br s, 1H), 9.94 (br s, 
1H), 9.25 (s, 1H), 8.55 (d, J = 1.7 Hz, 1H), 7.89 (dd, J = 8.5, 1.9 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.61 (d, 
J = 2.6 Hz, 1H), 7.20 (dd, J = 8.8, 2.6 Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H), 3.23 (s, 3H); 13C-NMR (126 MHz, 
DMSO-d6): δ (ppm) 163.39, 152.08, 149.15, 134.69, 131.79, 130.45, 124.81, 121.71, 120.89, 119.56, 119.36, 
116.68, 44.09; HRMS (ESI) calcd for C15H12ClN3O4S2 [M + H]+ 398.0031, found 398.0048. 
1-(3-Chloro-4-hydroxyphenyl)-3-(6-((trifluoromethyl)sulfonyl)benzo[d]thiazol-2-yl)urea (67) 
Yield 94%; mp: 267–269 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 11.40 (br s, 1H), 10.01 (s, 
1H), 9.10 (br s, 1H), 8.89 (s, 1H), 8.02 (dd, J = 8.6, 1.9 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 2.5 
Hz, 1H), 7.21 (dd, J = 8.7, 2.3 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H); 13C-NMR (75 MHz, DMSO-d6): δ (ppm) 
166.05, 155.92, 149.35, 133.47, 130.23, 128.07, 126.29, 121.75, 121.17, 119.85, 119.36, 117.44, 116.67, 40.35, 
40.08, 39.80, 39.52, 39.24, 38.96, 38.69; HRMS (ESI) calcd for C15H9ClF3N3O4S2 [M + H]+ 451.9748, found 
451.9749. 
1-(3-Chloro-4-hydroxyphenyl)-3-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)urea (71) 
Yield 58%; mp: 258–260 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.91 (br s, 1H), 7.55 (d, J = 
2.4 Hz, 1H), 7.14 (dd, J = 8.7, 2.4 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 2.59 (s, 2H), 2.54 (s, 2H), 1.75 (s, 4H); 
13C-NMR (126 MHz, DMSO-d6): δ (ppm) 158.38, 151.01, 149.02, 138.46, 130.54, 120.47, 120.31, 119.38, 
119.00, 116.77, 24.13, 22.46, 22.07, 21.82; HRMS (ESI) calcd for C14H14ClN3O2S [M + H]+ 324.05680, 
found 324.05634. 
1-(3-Chloro-4-hydroxyphenyl)-3-(2,3-dihydro-1H-inden-2-yl)urea (72) 
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Yield 21%; mp: 203–205 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.59 (br s, 1H), 8.14 (br s, 
1H), 7.52 (d, J = 2.6 Hz, 1H), 7.29 – 7.19 (m, 2H), 7.19 – 7.10 (m, 2H), 6.97 (dd, J = 8.7, 2.6 Hz, 1H), 6.83 
(d, J = 8.7 Hz, 1H), 6.36 (d, J = 7.3 Hz, 1H), 4.48 – 4.31 (m, 1H), 3.25 – 3.09 (m, 2H), 2.84 – 2.67 (m, 2H); 
13C-NMR (126 MHz, DMSO-d6): δ (ppm) 155.00, 147.38, 141.23, 132.93, 126.40, 124.56, 119.34, 119.16, 
117.90, 116.55, 50.77, 39.70; HRMS (ESI) calcd for C16H15ClN2O2 [M + H]+ 303.08948, found 303.08908. 
1-(3-Chloro-4-hydroxyphenyl)-3-(4-(4-chlorophenyl)thiazol-2-yl)urea (73) 
Yield 71%; mp: 206–208 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 10.69 (s, 1H), 9.91 (s, 1H), 
8.76 (s, 1H), 7.92 – 7.87 (m, 2H), 7.60 – 7.57 (m, 2H), 7.50 – 7.45 (m, 2H), 7.14 (dd, J = 8.7, 2.6 Hz, 1H), 
6.93 (d, J = 8.7 Hz, 1H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 159.31, 151.59, 148.87, 147.41, 133.16, 
132.07, 130.69, 128.67, 127.26, 120.67, 119.34, 116.66, 107.89; HRMS (ESI) calcd for C16H11Cl2N3O2S [M 
+ H]+ 380.00218, found 380.00168. 
1-(3-Chloro-4-hydroxyphenyl)-3-(thiazol-2-yl)urea (74) 
Yield 74%; mp: 220–222 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.83 (s, 1H), 9.81 (s, 1H), 7.56 
(d, J = 2.6 Hz, 1H), 7.47 (dd, J = 3.9, 1.6 Hz, 1H), 7.20 (dd, J = 3.8, 1.5 Hz, 1H), 7.15 (dd, J = 8.8, 2.6 Hz, 
1H), 6.95 (d, J = 8.7 Hz, 1H); 13C-NMR (126 MHz, DMSO-d6): δ (ppm) 160.49, 151.25, 149.00, 133.59, 
130.64, 120.41, 119.39, 119.08, 116.78, 113.06; HRMS (ESI) calcd for C10H8ClN3O2S [M + H]+ 270.0099, 
found 270.0099. 
1-(3-Chloro-4-hydroxyphenyl)-3-(4-methoxyphenethyl)urea (75) 
Yield 21%; mp: 161.5–163.5 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.58 (br s, 1H), 8.29 (br s, 
1H), 7.52 (d, J = 2.5 Hz, 1H), 7.14 (d, J = 8.5 Hz, 2H), 6.97 (dd, J = 8.7, 2.5 Hz, 1H), 6.89 – 6.84 (m, 2H), 
6.82 (d, J = 8.7 Hz, 1H), 5.98 (t, J = 5.5 Hz, 1H), 3.72 (s, 3H), 3.33 – 3.19 (m, 2H), 2.66 (t, J = 7.2 Hz, 2H); 
13C-NMR (126 MHz, DMSO-d6): δ (ppm) 157.65, 155.20, 147.32, 133.06, 131.35, 129.58, 119.37, 119.14, 
117.90, 116.54, 113.78, 54.97, 40.87, 34.96; HRMS (ESI) calcd for C16H17ClN2O3 [M + H]+ 321.10005, 
found 321.09967. 
1-(Benzo[d]thiazol-6-yl)-3-(3-chloro-4-hydroxyphenyl)urea (76) 
Yield 24%; mp: 224–226 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.77 (s, 1H), 9.20 (s, 1H), 8.89 
(s, 1H), 8.60 (s, 1H), 8.35 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 2.6 Hz, 1H), 7.47 (dd, J 
= 8.8, 2.2 Hz, 1H), 7.11 (dd, J = 8.7, 2.6 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H); 13C-NMR (126 MHz, DMSO-
d6): δ (ppm) 153.69, 152.69, 148.26, 148.17, 137.64, 134.46, 131.92, 122.92, 120.22, 119.26, 118.82, 118.11, 
116.63, 110.26; HRMS (ESI) calcd for C14H10ClN3O2S [M + H]+ 320.0255, found 320.0264. 
1,3-Bis(3-chloro-4-hydroxyphenyl)urea (78) 
Yield 94%; mp: 254.5–256.5 °C; 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 9.71 (br s, 2H), 8.43 (br s, 
2H), 7.54 (d, J = 2.6 Hz, 2H), 7.06 (dd, J = 8.8, 2.6 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H); 13C-NMR (126 MHz, 
DMSO-d6): δ (ppm) 152.77, 147.99, 132.14, 120.11, 119.22, 118.71, 116.59; HRMS (ESI) calcd for 
C13H10Cl2N2O3 [M + H]+ 313.01412, found 313.01361. 
4.3. β-HSD10 Enzymatic Activity Assay: 
Purification of 17β-HSD10 protein was performed as described in our previous work [22]. 
Compound screening, dose response and mechanism of inhibition experiments were performed 
as described in Hroch et al. 2016, with the exceptions being an alteration in assay buffer (10 mM Tris 
HCl (pH 7.4), 150 mM NaCl, 1 mM DTT, 0.005% Tween20, 0.01% BSA) and a change in temperature 
to 25 °C, to improve enzyme stability and assay reliability as compound solubility improved, as 
outlined in our previous work [19].  
Orthogonal screening (small molecule aggregation and redox cycling experiments) was carried 
out as described in our previous work [19]. 
4.4. Lactate Dehydrogenase (LDH) Cytotoxicity Assay:  
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Cell cytotoxicity was assessed via the measurement of lactate dehydrogenase leakage into the 
culture medium using a commercially available kit from Pierce (Thermo Scientific, UK, cat no. 88953). 
This was carried out in accordance with the kit guidelines, with the activity of LDH being calculated 
from the change in absorbance at 340 nm as NADH is reduced. HEK293 cells overexpressing mts17β-
HSD10 were cultured in phenol-red free media (10% FBS, 1 mM Sodium Pyruvate, 100 units 
Penicillin, 0.1 mg/mL Streptomycin and 2 mM L-Glutamine) and seeded at a density of 10,000 cells 
per well (100 μL, 96-well plates). Cells were then treated with compound of interest at 2 
concentrations (25 μM and 100 μM in DMSO) in triplicate. Treated cells were then incubated at 37 °C 
and CO2 (5%) for 24 hours before the LDH assay was performed as per the manufacturer’s 
instructions. Spontaneous control (water) and maximum control (lysis buffer) used in accordance 
with the kit guide. Absorbance was measured at 490 nm and 680 nm using the SpectraMaxM2e 
spectrophotometer (Molecular Devices, San Jose, CA, USA). The measured LDH activity was used to 
calculate % cytotoxicity using the following equation:  
% cytotoxicity = ሺcompound treated LDH Activity − Spontaneous LDH ActivityሻሺMaximum LDH Activity − Spontaneous LDH Activityሻ  x100 (1) 
4.5. (−)-CHANA Assay – In Vitro Dose Response and EC50 Determination: 
HEK293 mts17β-HSD10 cells were seeded at a density of 10,000 cells per well (100 μL, 96-well 
black plates, Greiner Cat no. 655090) in phenol-red free media (10% FBS, 1 mM Sodium Pyruvate, 100 
units Penicillin, 0.1 mg/mL Streptomycin and 2 mM L-Glutamine). The media was removed from the 
cells and replaced with fresh media containing varying concentrations of compound (100 μM–0.098 
μM). The fluorogenic probe (−)-CHANA was then added to each well to give a final assay 
concentration of 20 μM. Fluorescence was immediately measured using the FLUOstar Optima 
microplate reader (excitation = 380 nm, emission = 520 nm, orbital averaging = 3 mm) and the initial 
reaction monitored for 3–4 hours. EC50 was calculated from the control - subtracted triplicates using 
non-linear regression (four parameters) of GraphPad Prism 5 software. Final EC50 and SEM value was 
obtained as a mean of at least 3 independent measurements. 
Supplementary Materials: The following are available online, Figure S1: IC50 Graphs for compounds 5, 6, 61, 62, 
63, 64, 65, 66, 67 and 78, Figure [S2]: Hanes-Woolf kinetic plots for compounds 5, 6 and 61. Figure [S3]: Hanes-
Woolf kinetic plots for compounds 62, 63 and 64. Figure [S4]: Hanes-Woolf kinetic plots for compounds 65, 66, 
67 and 61. Figure [S5]: Cellular IC50 Graphs for compounds 5, 6, 61, 62, 63, 64, 65, 66, 67 and 78.Table S1: Full 
primary screen compound in vitro evaluation.  
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